Literature DB >> 18706241

Transplantation of autologous bone marrow mononuclear cells for patients with lower limb ischemia.

Yong-quan Gu1, Jian Zhang, Lian-rui Guo, Li-xing Qi, Shu-wen Zhang, Juan Xu, Jian-xin Li, Tao Luo, Bing-xin Ji, Xue-feng Li, Heng-xi Yu, Shi-jun Cui, Zhong-gao Wang.   

Abstract

BACKGROUND: Many treatment options for lower limb ischemia are difficult to apply for the patients with poor arterial outflow or with poor general conditions. The effect of medical treatment alone is far from ideal, especially in patients with diabetic foot. A high level amputation is inevitable in these patients. This study aimed to explore the effect of transplantation of autologous bone marrow mononuclear cells on the treatment of lower limb ischemia and to compare the effect of intra-arterial transplantation with that of intra-muscular transplantation.
METHODS: In this clinical trial, 32 patients with lower limb ischemia were divided into two groups. Group 1 (16 patients with 18 affected limbs) received transplantation of autologous bone marrow mononuclear cells by intra-muscular injection into the affected limbs; and group 2 (16 patients with 17 affected limbs) received transplantation of autologous bone marrow mononuclear cells by intra-arterial injection into the affected limbs. Rest pain, coldness, ankle/brachial index (ABI), claudication, transcutaneous oxygen pressure (tcPO(2)) and angiography (15 limbs of 14 patients) were evaluated before and after the mononuclear cell transplantation to determine the effect of the treatment.
RESULTS: Two patients died from heart failure. The improvement of rest pain was seen in 76.5% (13/17) of group 1 and 93.3% (14/15) of group 2. The improvement of coldness was 100% in both groups. The increase of ABI was 44.4% (8/18) in group 1 and 41.2% (7/17) in group 2. The value of tcPO(2) increased to 20 mmHg or more in 20 limbs. Nine of 15 limbs which underwent angiography showed rich collaterals. Limb salvage rate was 83.3% (15/18) in group 1 and 94.1% (16/17) in group 2. There was no statistically significant difference in the effectiveness of the treatment between the two groups.
CONCLUSIONS: Transplantation of autologous bone marrow mononuclear cells is a simple, safe and effective method for the treatment of lower limb ischemia, and the two approaches for the implantation, intra-muscular injection and intra-arterial injection, show similar results.

Entities:  

Mesh:

Year:  2008        PMID: 18706241

Source DB:  PubMed          Journal:  Chin Med J (Engl)        ISSN: 0366-6999            Impact factor:   2.628


  12 in total

1.  Efficacy, safety and influencing factors of intra-calf muscular injection of bone marrow mononuclear cells in the treatment of type 2 diabetes mellitus-induced lower extremity vascular disease.

Authors:  Hui-Min Zhou; Fan Liu; Ai-Ge Yang; Yu-Qing Guo; Ya-Ru Zhou; Yong-Quan Gu; Bao-Yong Yan; Quan-Hai Li
Journal:  Exp Ther Med       Date:  2017-09-22       Impact factor: 2.447

2.  Autologous cells derived from different sources and administered using different regimens for 'no-option' critical lower limb ischaemia patients.

Authors:  S Fadilah Abdul Wahid; Nor Azimah Ismail; Wan Fariza Wan Jamaludin; Nor Asiah Muhamad; Muhammad Khairul Azaham Abdul Hamid; Hanafiah Harunarashid; Nai Ming Lai
Journal:  Cochrane Database Syst Rev       Date:  2018-08-29

3.  A phase II trial of autologous transplantation of bone marrow stem cells for critical limb ischemia: results of the Naples and Pietra Ligure Evaluation of Stem Cells study.

Authors:  Alessandro Schiavetta; Ciro Maione; Chiara Botti; Gennaro Marino; Stefano Lillo; Alberto Garrone; Lorella Lanza; Stefano Pagliari; Andrea Silvestroni; Giuseppe Signoriello; Vincenzo Sica; Gilda Cobellis
Journal:  Stem Cells Transl Med       Date:  2012-07-06       Impact factor: 6.940

Review 4.  Local intramuscular transplantation of autologous mononuclear cells for critical lower limb ischaemia.

Authors:  Kasra Moazzami; Bobak Moazzami; Aria Roohi; Saharnaz Nedjat; Elena Dolmatova
Journal:  Cochrane Database Syst Rev       Date:  2014-12-19

5.  Safety and Effectiveness of Bone Marrow Cell Concentrate in the Treatment of Chronic Critical Limb Ischemia Utilizing a Rapid Point-of-Care System.

Authors:  Venkatesh Ponemone; Saniya Gupta; Dalip Sethi; Manish Suthar; Monika Sharma; Richard J Powell; Kenneth Lee Harris; Nungshi Jungla; Priyadarshini Arambam; Upendra Kaul; Ashok Seth; Suhail Bukhari
Journal:  Stem Cells Int       Date:  2017-01-17       Impact factor: 5.443

6.  Feasibility investigation of allogeneic endometrial regenerative cells.

Authors:  Zhaohui Zhong; Amit N Patel; Thomas E Ichim; Neil H Riordan; Hao Wang; Wei-Ping Min; Erik J Woods; Michael Reid; Eduardo Mansilla; Gustavo H Marin; Hugo Drago; Michael P Murphy; Boris Minev
Journal:  J Transl Med       Date:  2009-02-20       Impact factor: 5.531

Review 7.  Cell Therapy in Patients with Critical Limb Ischemia.

Authors:  Rita Compagna; Bruno Amato; Salvatore Massa; Maurizio Amato; Raffaele Grande; Lucia Butrico; Stefano de Franciscis; Raffaele Serra
Journal:  Stem Cells Int       Date:  2015-08-02       Impact factor: 5.443

Review 8.  Autologous bone marrow cell therapy for peripheral arterial disease.

Authors:  C Botti; C Maione; A Coppola; V Sica; G Cobellis
Journal:  Stem Cells Cloning       Date:  2012-09-06

9.  Autologous bone marrow-derived mononuclear cell therapy in Chinese patients with critical limb ischemia due to thromboangiitis obliterans: 10-year results.

Authors:  Jianming Guo; Lianrui Guo; Shijun Cui; Zhu Tong; Alan Dardik; Yongquan Gu
Journal:  Stem Cell Res Ther       Date:  2018-02-22       Impact factor: 6.832

10.  Locally Delivered Umbilical Cord Mesenchymal Stromal Cells Reduce Chronic Inflammation in Long-Term Nonhealing Wounds: A Randomized Study.

Authors:  Yulia Suzdaltseva; Sergey Zhidkih; Sergey L Kiselev; Victor Stupin
Journal:  Stem Cells Int       Date:  2020-02-14       Impact factor: 5.443

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.